EMVision adds traumatic brain injury to First Responder opportunity
EMVision Medical Devices has secured a new $3 million non-dilutive CRC-P grant to adapt and clinically test its First Responder scanner for traumatic brain injury. The project adds a second potential indication to the device, but remains dependent on funding agreements, clinical evidence and regulatory clearance.
- $3 million CRC-P grant for traumatic brain injury development
- First Responder to be tested for traumatic intracranial haemorrhage and concussion
- Company estimates TBI could more than double consumables opportunity
- Protocol and ethics work planned for H1 CY27, with study activation in H2 CY27
- Grant remains subject to Commonwealth and partner agreements
Add us as a preferred source on Google
Grant adds a second indication for First Responder
EMVision Medical Devices Limited (ASX:EMV) has won a fresh $3 million Australian Government grant to take its portable First Responder brain scanner into traumatic brain injury, extending the device beyond its existing stroke-focused development work. The CRC-P funding is non-dilutive, although it sits within a matched funding program and remains subject to Commonwealth and partner agreements.

The project will focus primarily on detecting traumatic intracranial haemorrhage, using clinical data and paired CT or MRI scans to train and test algorithms. EMVision also plans to explore whether the device can identify scan characteristics associated with concussion, where diagnosis currently relies largely on clinical assessment of symptoms.
First Responder moves from feasibility toward TBI evidence

The announcement gives the First Responder a larger potential role in settings where CT access is delayed or unavailable, including ambulances, aged-care facilities, regional healthcare, sporting venues and military environments. The company says a TBI capability could help distinguish patients who need urgent hospital or specialist care from those who may not require immediate transfer, but that proposition still needs to be demonstrated clinically.
The expansion builds on the device’s developing point-of-care stroke use case. EMVision recently completed a small roadside feasibility study in which the scanner was used in homes, ambulances and a workplace, with the company reporting an average scan time of 6.7 minutes and no device-related adverse events. That work was exploratory and non-diagnostic, rather than evidence that the device can detect traumatic bleeding. The earlier programme is covered in the First Responder roadside study.
TBI could broaden the commercial case
EMVision estimates that adding TBI detection could more than double the addressable consumables opportunity for First Responder under its planned per-scan revenue model, based on the relative incidence of TBI and stroke in target markets. That is a company estimate, not a forecast, and it depends on the device securing evidence and regulatory clearance for the new indication.
The company points to an estimated 2.8 million TBI-related emergency department visits, hospitalisations and deaths in the United States each year, compared with about 800,000 strokes. It also identifies aged care as a particular use case because falls are common among older people and blood-thinning medication can increase bleeding risk. The figures describe the scale of the potential need, not demonstrated demand for EMVision’s product.
Clinical timetable begins with agreements
Project activities are scheduled to start in the first quarter of calendar 2027. EMVision expects to complete the Commonwealth Funding Agreement and partner agreements in the coming months, with Metro North Hospital and Health Service and Titan Prehospital Innovation participating in the project.
Protocol and ethics work is planned for the first half of 2027, followed by study activation in the second half. The proposed work includes human factors and safety evaluation in emergency settings, plus preliminary sensitivity and specificity testing against hospital CT as the reference standard. First Responder is not currently approved for TBI or intracranial haemorrhage detection in any jurisdiction, leaving the clinical and regulatory path ahead as the material test of the grant’s commercial promise.
Bottom Line?
The grant removes some funding pressure from a potentially larger device opportunity, but the investment case now turns on agreement execution, study activation and credible TBI diagnostic results.
Questions in the middle?
- When will EMVision and its partners execute the agreements needed to unlock the CRC-P project?
- Can First Responder generate useful sensitivity and specificity results for traumatic intracranial haemorrhage against CT imaging?
- Will a validated TBI indication translate into higher device utilisation and recurring consumables revenue?
Sources
1-
New $3m Grant Unlocks Traumatic Brain Injury Opportunity (opens in a new tab)Verified source. Emvision Medical Devices Ltd · 20 Nov 2026